McKesson Corporation ($MCK) Stock Forecast: Down 5.4% Today

What is McKesson Corporation?

McKesson Corporation (MCK) is a pharmaceutical products distributor known for its focus on high-growth healthcare verticals and strong financial performance. Despite challenges in core distribution margins, the company has been outperforming the industry and S&P 500.

Why is McKesson Corporation going down?

MCK stock is down 5.4% on Mar 20, 2026 14:10

• The strong bearish movement in McKesson's stock today could be attributed to profit-taking by insiders despite the positive quarterly earnings and analyst recommendations.
• The acquisition of shares by CIBC Bancorp USA Inc. might have initially boosted investor confidence, but the subsequent insider selling could have raised concerns among traders.
• The price target adjustment to $1,010 from $974, while maintaining an Outperform rating, could have created uncertainty among investors, leading to a sell-off.
• Overall, the mixed signals from insider selling, institutional acquisitions, and price target adjustments might have contributed to the bearish market movement in McKesson's stock today.

MCK Price Chart

MCK Technical Analysis

MCK News

Here's Why You Should Add McKesson Stock to Your Portfolio Now

McKesson (MCK) is recommended as a strong buy due to its robust Q3 fiscal 2026 results, driven by double-digit growth in specialty distribution, oncology, and biopharma solutions. The company's focus on high-growth healthcare verticals and strong financial performance—outperforming the industry and S&P 500—makes it an attractive investment, despite challenges in core distribution margins and the Medical-Surgical segment. Analysts project continued strong growth in revenue and earnings per share for fiscal 2026.

https://www.tradingview.com/news/zacks:f1d8d718e094b:0-here-s-why-you-should-add-mckesson-stock-to-your-portfolio-now/

CIBC Bancorp USA Inc. Acquires Shares of 17,187 McKesson Corporation $MCK

CIBC Bancorp USA Inc. recently acquired 17,187 shares of McKesson Corporation, valued at approximately $13.28 million, making it a new institutional stakeholder in the company. McKesson reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.82 per share. Despite significant institutional ownership and a "Moderate Buy" analyst rating, insiders have been net sellers of the stock.

https://www.marketbeat.com/instant-alerts/filing-cibc-bancorp-usa-inc-acquires-shares-of-17187-mckesson-corporation-mck-2026-03-20/

McKesson Corporation opens registration for ideaShare 2026 to unite pharmacy professionals

McKesson Corporation has opened registration for its annual ideaShare 2026 event, aiming to strengthen the independent pharmacy sector through networking and innovation. This initiative builds on previous strategic moves like a patient hub model for cell and gene therapies and funding for state pharmacy associations, demonstrating McKesson's commitment to advancing patient care and pharmacy business resilience. The event seeks to offer crucial resources and opportunities for pharmacy professionals.

https://tradersunion.com/news/companies/show/1745988-mckesson-ideashare-registration/

FinancialContent - First Fully Autonomous Telehealth AI Robot Enables Remote Clinicians to Navigate Hospitals Without Staff Assistance; Introduction at HIMSS 2026 from VSee Health, Inc. (Nasdaq: VSEE)

VSee Health, Inc. (Nasdaq: VSEE) has introduced the VSee AI Robot, the world's first fully autonomous telehealth AI robot capable of navigating hospitals and reaching patients' bedsides without staff assistance. This innovation, unveiled at HIMSS 2026, aims to revolutionize virtual rounding, telestroke response, and specialist coverage by integrating seamlessly into clinical AI ecosystems. The company also highlighted recent strategic partnerships and a $6.0 million private placement.

https://markets.financialcontent.com/stocks/article/getnews-2026-3-19-first-fully-autonomous-telehealth-ai-robot-enables-remote-clinicians-to-navigate-hospitals-without-staff-assistance-introduction-at-himss-2026-from-vsee-health-inc-nasdaq-vsee

Baird Adjusts Price Target on McKesson to $1,010 From $974, Maintains Outperform Rating

Baird has raised its price target on McKesson Corporation (NYSE: MCK) to $1,010 from $974, while reiterating an Outperform rating on the stock. This adjustment comes as financial analysts continue to review and update their outlooks for the pharmaceutical products distributor. Other firms, including Argus, Deutsche Bank, and Leerink Partners, have also recently adjusted their price targets for McKesson, generally maintaining positive ratings.

https://www.marketscreener.com/news/baird-adjusts-price-target-on-mckesson-to-1-010-from-974-maintains-outperform-rating-ce7e5ededa8af727

Trending Today

General Electric Company ($GE) Stock Forecast: Down 5.0% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.0% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 3.6% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 5.3% Today

C.H. Robinson Worldwide Inc. ($CHRW) Stock Forecast: Up 8.4% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 15.0% Today

Charles Schwab Corporation (The) ($SCHW) Stock Forecast: Down 7.4% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.6% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Up 5.4% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 10.2% Today

McKesson Corporation Price History

02.00.2026 - MCK Stock was up 1.4%

• Accurate Wealth Management LLC and Allspring Global Investments Holdings LLC notably increased their holdings in McKesson Corporation, signaling a rise in confidence in the company's future.
• McKesson's Q3 earnings exceeded expectations, with a 10.2% year-over-year revenue growth, surpassing EPS projections. This strong financial performance likely contributed to the uptick in the stock.
• Analysts uphold a "Moderate Buy" consensus rating on McKesson, with a target price of $892.86, reflecting positivity about the company's growth potential.
• The steady performance of McKesson shares relative to the NYSE Composite Index highlights the company's consistent and reliable position in the market, making it an attractive investment option.

05.01.2026 - MCK Stock was up 16.6%

• McKesson experienced a strong bullish movement today due to robust fiscal third-quarter results, particularly in key segments like oncology and pharmaceutical distribution.
• The planned IPO of its medical surgical business by the second half of 2027 demonstrates a strategic shift towards a more focused approach.
• Positive sentiment surrounding McKesson's financial performance and surpassing analyst expectations have led to an all-time high stock price, boosting investor confidence.
• McKesson's solid operational strategies, strong financial results, and growth potential in the healthcare sector have made it an attractive investment option, contributing to the bullish market movement.

05.01.2026 - MCK Stock was up 13.6%

• Strong fiscal third-quarter results were reported by McKesson, with a focus on oncology, biopharma services, and pharmaceutical distribution, leading to a bullish market movement.
• The company's strategic shift towards its core drug distribution and services, as well as the potential IPO of its medical surgical business, has garnered positive investor sentiment and contributed to the stock's surge.
• Despite a Zacks Rank of #3 (Hold) and cautious outlook, the overall market response to McKesson's robust operational strategies and exceeding analyst expectations in Q3 fiscal 2026 results has been overwhelmingly positive, driving the stock to new heights.

05.01.2026 - MCK Stock was up 13.6%

• MCK witnessed a strong uptrend in trading today.
• This positive movement could be linked to the company's Q3 2026 results, where although revenue slightly missed expectations, the adjusted EPS exceeded forecasts. This robust performance and the raised annual profit guidance likely bolstered investor confidence.
• The favorable atmosphere in the healthcare domain, exemplified by Cardinal Health (CAH) surpassing estimates and revising its profit outlook due to heightened demand for specialized medications, may have further influenced MCK's upward trajectory.
• Investors seem positive about McKesson's strategic positioning in healthcare, particularly its emphasis on specialty pharmaceuticals and potential growth prospects within the market.

26.08.2025 - MCK Stock was up 5.4%

• The stock of McKesson had a strong bullish movement today, outperforming the broader market.
• Information points to the long-term growth potential of investing in McKesson, showcasing how a $1000 investment made years ago would have significantly appreciated.
• Despite a recent dip in stock price, McKesson has historically shown resilience and strong performance, with an average annual return of 14.69% over the past 20 years.
• The positive movement in McKesson's stock price today could be attributed to the company's consistent growth trajectory and investor confidence in its long-term prospects, despite short-term fluctuations.

08.00.2026 - MCK Stock was down 2.2%

• The bearish movement in MCK's stock today could be attributed to the insider selling activity by Thomas Rodgers, the Chief Strategy & Business Development Officer. This could have raised concerns among investors about the company's future prospects.
• The fresh analyst commentary on McKesson's valuation, while highlighting its strong performance and earnings potential, may not have been enough to offset the impact of the insider selling news.
• The overall market sentiment towards healthcare supply chain companies like McKesson might have been affected by the potential risks mentioned, such as drug pricing pressures and vertical integration by manufacturers, leading to a bearish trend in the stock price.
• Despite the positive outlook on injectable GLP-1 drugs driving demand for related companies like West Pharmaceutical Services, the focus on McKesson's insider selling and valuation concerns could have overshadowed any potential industry growth prospects, contributing to the bearish movement in the stock.

05.00.2026 - MCK Stock was down 1.5%

• An increase in Motco's stake in McKesson Corporation might have initially boosted investor confidence, but various other factors could have shifted the overall market sentiment.
• The lowering of Cencora's price target by B of A Securities may have affected the pharmaceutical sector, including McKesson Corporation, leading to a bearish market trend.
• Despite positive news about the growth of the Palliative Care Market and McKesson's strong performance, the stock faced downward pressure possibly due to broader market conditions or specific internal concerns.
• Varied opinions on the stock performance and stability of Cencora Inc. in comparison to McKesson Corporation could have influenced investors to reallocate their funds, impacting McKesson's stock price negatively.

20.02.2026 - MCK Stock was down 5.4%

• The strong bearish movement in McKesson's stock today could be attributed to profit-taking by insiders despite the positive quarterly earnings and analyst recommendations.
• The acquisition of shares by CIBC Bancorp USA Inc. might have initially boosted investor confidence, but the subsequent insider selling could have raised concerns among traders.
• The price target adjustment to $1,010 from $974, while maintaining an Outperform rating, could have created uncertainty among investors, leading to a sell-off.
• Overall, the mixed signals from insider selling, institutional acquisitions, and price target adjustments might have contributed to the bearish market movement in McKesson's stock today.

05.02.2026 - MCK Stock was down 5.1%

• The announcement of a forthcoming CFO transition elicited uncertainty among investors, potentially prompting a sell-off of McKesson stock.
• EVP Michele Lau's insider selling of shares, despite the company's robust Q3 fiscal 2026 performance, could have indicated to investors a profit-taking behavior among insiders.
• Negative market sentiment towards McKesson may have been fueled by broader industry developments, including upcoming conferences highlighting risks and debt concerns in related companies like Henry Schein.
• The stock's decline in midday trading, coupled with a notable decrease in executive ownership, likely influenced the bearish movement as investors reassessed their positions in McKesson.

05.02.2026 - MCK Stock was down 5.9%

• The decline in McKesson's stock price could be linked to the upcoming CFO transition, causing investor uncertainty about the company's future strategic and financial direction.
• The sale of $2.69 million in stock by McKesson's EVP and Chief Legal Officer may have also influenced the negative investor sentiment, highlighting insider selling activities.
• Despite outperforming analyst projections in Q3 fiscal 2026, concerns regarding the CFO transition and insider selling could have overshadowed this positive achievement, resulting in the decline in the stock market.
• Investors are likely keeping a close eye on McKesson's upcoming capital allocation strategies, including the potential Med-Surg spin-off and specialty acquisitions, to evaluate their potential impact on the company's financial prospects and stock performance.

12.01.2026 - MCK Stock was down 4.2%

• The stock of McKesson (MCK) experienced a bearish movement despite positive developments and strong third-quarter results.
• The refocusing on North American operations and the spin-off of the medical-surgical segment might have initially raised concerns among investors about the company's future growth prospects.
• Interoperability challenges in the healthcare sector could have contributed to market uncertainty, potentially impacting McKesson's stock performance.
• Despite positive outlook from analysts and the company's strategic moves, investors may be cautious about the potential risks associated with the shift in focus and the broader industry challenges.

06.00.2026 - MCK Stock was up 1.8%

• An institutional investor, Robeco Institutional Asset Management B.V., notably increased its holdings in McKesson Corporation, indicating strong confidence in the company's future.
• McKesson's Q3 earnings surpassed expectations, with earnings per share exceeding forecasts and a 10.2% revenue growth from the previous year, potentially boosting investor confidence.
• The company's emphasis on specialty and automation services, coupled with strategic expansions like venturing into the biopharma and provider ecosystem, played a key role in driving its positive earnings trajectory.
• Positive sentiments from analysts, institutional investors, and the company's financial performance likely contributed to the recent bullish movement in McKesson's stock.